Compare BNTC & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNTC | EDD |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.7M | 345.5M |
| IPO Year | N/A | N/A |
| Metric | BNTC | EDD |
|---|---|---|
| Price | $13.09 | $5.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $28.25 | N/A |
| AVG Volume (30 Days) | 253.4K | ★ 254.3K |
| Earning Date | 02-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.70 | $4.22 |
| 52 Week High | $17.15 | $4.95 |
| Indicator | BNTC | EDD |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 51.39 |
| Support Level | $10.99 | $5.47 |
| Resistance Level | $13.36 | $5.55 |
| Average True Range (ATR) | 0.94 | 0.07 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 84.69 | 26.09 |
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.